Jason Butler
Stock Analyst at JMP Securities
(4.63)
# 217
Out of 5,041 analysts
142
Total ratings
52.41%
Success rate
39.1%
Average return
Main Sectors:
Stocks Rated by Jason Butler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AQST Aquestive Therapeutics | Maintains: Market Outperform | $9 → $12 | $7.02 | +71.06% | 8 | Oct 9, 2025 | |
| PRTA Prothena Corporation | Maintains: Market Outperform | $29 → $11 | $9.75 | +12.82% | 11 | Sep 2, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Market Outperform | $33 → $95 | $90.47 | +5.01% | 4 | Jul 23, 2025 | |
| RAPP Rapport Therapeutics | Reiterates: Market Outperform | $28 | $26.19 | +6.91% | 2 | Jul 8, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Market Outperform | $37 | $21.73 | +70.27% | 15 | Jun 26, 2025 | |
| GHRS GH Research | Reiterates: Market Outperform | $39 | $13.27 | +193.90% | 5 | Jun 24, 2025 | |
| PGEN Precigen | Reiterates: Market Outperform | $6 | $4.25 | +41.18% | 11 | Jun 12, 2025 | |
| TTD The Trade Desk | Maintains: Market Outperform | $115 → $100 | $54.13 | +84.74% | 1 | May 9, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Market Outperform | $42 → $38 | $22.07 | +72.18% | 8 | May 7, 2025 | |
| CYTK Cytokinetics | Reiterates: Market Outperform | $78 | $57.50 | +35.65% | 16 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $17 → $18 | $10.68 | +68.54% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $4 | $2.68 | +49.25% | 7 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $696 → $701 | $812.18 | -13.69% | 8 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $29 → $33 | $10.19 | +223.85% | 1 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $8 → $9 | $9.02 | -0.22% | 8 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $72 → $73 | $66.89 | +9.14% | 13 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.99 | - | 7 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $11.31 | +67.99% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $22 | $1.63 | +1,249.69% | 1 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $4.87 | - | 1 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $42,000 | $13.40 | +313,332.84% | 1 | Dec 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $111 → $116 | $10.67 | +987.16% | 4 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $9 | $4.28 | +110.28% | 1 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.56 | - | 1 | Dec 2, 2020 |
Aquestive Therapeutics
Oct 9, 2025
Maintains: Market Outperform
Price Target: $9 → $12
Current: $7.02
Upside: +71.06%
Prothena Corporation
Sep 2, 2025
Maintains: Market Outperform
Price Target: $29 → $11
Current: $9.75
Upside: +12.82%
ABIVAX Société Anonyme
Jul 23, 2025
Maintains: Market Outperform
Price Target: $33 → $95
Current: $90.47
Upside: +5.01%
Rapport Therapeutics
Jul 8, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $26.19
Upside: +6.91%
ACADIA Pharmaceuticals
Jun 26, 2025
Reiterates: Market Outperform
Price Target: $37
Current: $21.73
Upside: +70.27%
GH Research
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $39
Current: $13.27
Upside: +193.90%
Precigen
Jun 12, 2025
Reiterates: Market Outperform
Price Target: $6
Current: $4.25
Upside: +41.18%
The Trade Desk
May 9, 2025
Maintains: Market Outperform
Price Target: $115 → $100
Current: $54.13
Upside: +84.74%
Viridian Therapeutics
May 7, 2025
Maintains: Market Outperform
Price Target: $42 → $38
Current: $22.07
Upside: +72.18%
Cytokinetics
Apr 10, 2025
Reiterates: Market Outperform
Price Target: $78
Current: $57.50
Upside: +35.65%
Mar 12, 2025
Maintains: Market Outperform
Price Target: $17 → $18
Current: $10.68
Upside: +68.54%
Mar 5, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $2.68
Upside: +49.25%
Feb 28, 2025
Maintains: Outperform
Price Target: $696 → $701
Current: $812.18
Upside: -13.69%
Feb 21, 2025
Maintains: Market Outperform
Price Target: $29 → $33
Current: $10.19
Upside: +223.85%
Feb 13, 2025
Maintains: Market Outperform
Price Target: $8 → $9
Current: $9.02
Upside: -0.22%
Nov 1, 2024
Maintains: Market Outperform
Price Target: $72 → $73
Current: $66.89
Upside: +9.14%
Sep 4, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $3.99
Upside: -
Apr 9, 2024
Reiterates: Market Outperform
Price Target: $19
Current: $11.31
Upside: +67.99%
Sep 28, 2023
Initiates: Market Outperform
Price Target: $22
Current: $1.63
Upside: +1,249.69%
Oct 17, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $4.87
Upside: -
Dec 15, 2021
Initiates: Market Outperform
Price Target: $42,000
Current: $13.40
Upside: +313,332.84%
Nov 23, 2021
Maintains: Market Outperform
Price Target: $111 → $116
Current: $10.67
Upside: +987.16%
Nov 8, 2021
Maintains: Market Outperform
Price Target: $7 → $9
Current: $4.28
Upside: +110.28%
Dec 2, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $1.56
Upside: -